Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) Selling, General & Administrative Expenses
The sg&a expense for Labcorp Holdings Inc. (LH) is $2.22 Billion with a year-over-year change of -0.61%. Selling, General & Administrative (SG&A) expenses include all costs related to selling products and running the business that are not directly tied to production.
LH SG&A Expense Chart
LH SG&A Expense
$2.22B+214.86% 20Y
Zoom
Current SG&A Expense
$2.22B
$2.22 Billion
Year-over-Year Change
-0.61%
vs. $2.23B prior year
Historical Data
30
Years of data available
Annual SG&A Expense History
| Year | SG&A Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.22B | $-13.70M | -0.61% |
| 2024 | $2.23B | +$208.60M | +10.32% |
| 2023 | $2.02B | +$24.80M | +1.24% |
| 2022 | $2.00B | +$306.30M | +18.12% |
| 2021 | $1.69B | $-39.00M | -2.26% |
| 2020 | $1.73B | +$104.80M | +6.45% |
| 2019 | $1.62B | +$53.60M | +3.41% |
| 2018 | $1.57B | $-241.50M | -13.32% |
| 2017 | $1.81B | +$182.20M | +11.18% |
| 2016 | $1.63B | +$8.20M | +0.51% |
| 2015 | $1.62B | +$423.80M | +35.37% |
| 2014 | $1.20B | +$69.40M | +6.15% |
| 2013 | $1.13B | +$14.20M | +1.27% |
| 2012 | $1.11B | $-45.00M | -3.88% |
| 2011 | $1.16B | +$125.30M | +12.11% |
| 2010 | $1.03B | +$75.40M | +7.86% |
| 2009 | $958.90M | +$23.80M | +2.55% |
| 2008 | $935.10M | +$126.40M | +15.63% |
| 2007 | $808.70M | +$29.60M | +3.80% |
| 2006 | $779.10M | +$75.20M | +10.68% |
| 2005 | $703.90M | +$54.80M | +8.44% |
| 2004 | $649.10M | $-2.70M | -0.41% |
| 2003 | $651.80M | +$66.30M | +11.32% |
| 2002 | $585.50M | +$69.00M | +13.36% |
| 2001 | $516.50M | +$33.50M | +6.94% |
| 2000 | $483.00M | +$34.80M | +7.76% |
| 1999 | $448.20M | +$43.20M | +10.67% |
| 1998 | $405.00M | $-94.90M | -18.98% |
| 1997 | $499.90M | +$9.90M | +2.02% |
| 1996 | $490.00M | — | — |
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter